DeLauro Renews Push To Give FDA Mandatory Recall Authority For Drugs
Executive Summary
"FDA’s failure to stop companies from selling ranitidine makes the United States government complicit in exposing infants and adults to the risk of cancer," says Rep. DeLauro in letter to FDA and HHS. She also re-introduced legislation proposing FDA have mandatory recall authority for drugs.
You may also be interested in...
FDA Finds Ranitidine Poses Little Risk, But Concerns Linger
Ranitidine no more carcinogenic than grilled meat, says FDA drug center director Janet Woodcock. Agency finds NDMA levels in ranitidine drugs well below those claimed by Valisure, online pharmacy asking FDA to order drug off US market.
Contamination In Common OTC Antacid Adds To FDA's API Impurity Concerns
Online Pharmacy Stirs Ranitidine Controversy With Petition To Halt Sales
After its tests showed ranitidine forms a nitrosamine impurity that is a probable carcinogen, Valisure asks FDA to suspend sales of antacid products containing the API. In citizen petition firm, online pharmacy also advises FDA to publish regulations requiring independent chemical testing, verification of drugs.
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests:
